We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-3.83%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$708M
AUM Growth
-$202M
Cap. Flow
-$159M
Cap. Flow %
-22.52%
Top 10 Hldgs %
51.4%
Holding
107
New
17
Increased
18
Reduced
23
Closed
41

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$39.7M
2
LLY icon
Eli Lilly
LLY
+$23M
3
MSFT icon
Microsoft
MSFT
+$17M
4
AMZN icon
Amazon
AMZN
+$14M
5
META icon
Meta Platforms (Facebook)
META
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 72.32%
2 Industrials 4.31%
3 Technology 3.78%
4 Financials 1.4%
5 Communication Services 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RLMD icon
26
Relmada Therapeutics
RLMD
$557M
$7.86M 1.11%
291,252
-186,956
-39% -$3.87M
TEVA icon
27
Teva Pharmaceuticals
TEVA
$40.8B
$7.82M 1.11%
832,878
+1
+0% +$8
KROS icon
28
Keros Therapeutics
KROS
$199M
$7.59M 1.07%
139,581
+19,900
+17% +$1.02M
SWTX
29
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$7.05M 1%
+125,000
New +$7.15M
RUN icon
30
CALL
Sunrun
RUN
$2.34B
$6.92M 0.98%
228,000
PERI icon
31
Perion Network
PERI
$375M
$6.88M 0.97%
306,051
+81,051
+36% +$1.73M
IMUX icon
32
Immunic
IMUX
$190M
$6.59M 0.93%
58,321
-8,339
-13% -$965K
VTGN icon
33
VistaGen Therapeutics
VTGN
$9.89M
$6.14M 0.87%
165,047
+30,882
+23% +$1.35M
V icon
34
Visa
V
$684B
$5.59M 0.79%
+25,200
New +$5.45M
ABNB icon
35
Airbnb
ABNB
$89.9B
$5.15M 0.73%
30,000
-17,689
-37% -$2.82M
IMTX icon
36
Immatics
IMTX
$1.18B
$4.97M 0.7%
621,925
RUN icon
37
Sunrun
RUN
$2.34B
$4.56M 0.64%
+150,000
New +$4.18M
CSTE icon
38
Caesarstone
CSTE
$72.3M
$4.5M 0.64%
428,046
-216,100
-34% -$2.56M
MA icon
39
Mastercard
MA
$502B
$4.32M 0.61%
+12,100
New +$4.35M
ABNB icon
40
CALL
Airbnb
ABNB
$89.9B
$4.17M 0.59%
+24,300
New +$3.87M
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$27.5B
$4.04M 0.57%
+24,768
New +$3.77M
NAUT icon
42
Nautilus Biotechnolgy
NAUT
$124M
$3.65M 0.52%
840,000
+40,000
+5% +$164K
REPL icon
43
Replimune Group
REPL
$941M
$3.61M 0.51%
+212,640
New +$4.01M
FATE icon
44
Fate Therapeutics
FATE
$286M
$3.47M 0.49%
89,425
-96,051
-52% -$3.72M
VRNA
45
DELISTED
Verona Pharma
VRNA
$3.33M 0.47%
666,339
-134,917
-17% -$785K
FIVN icon
46
FIVE9
FIVN
$2.11B
$3.28M 0.46%
29,699
-55,857
-65% -$6.5M
KZR
47
DELISTED
Kezar Life Sciences
KZR
$3.12M 0.44%
18,760
-14,969
-44% -$2.15M
ASND icon
48
Ascendis Pharma A/S
ASND
$16B
$3.11M 0.44%
+26,529
New +$3.07M
IS
49
DELISTED
ironSource Ltd.
IS
$2.98M 0.42%
+620,000
New +$3.77M
VINC
50
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$2.88M 0.41%
36,008

Similar funds

Sphera Funds Management's Q1 2022 Portfolio in Review

As of Q1 2022, Sphera Funds Management held 107 positions worth $708M, down 22% from $910M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management withdrew a net $159M in Q1 2022, closing 41 positions and reducing 23 holdings. Its most notable exit was Microsoft, an estimated $17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sphera Funds Management opened a new position in Novo Nordisk worth $26.4M.

  • Sphera Funds Management's largest Q1 2022 buy was Novo Nordisk: 474,800 shares worth $26.4M.
  • Sphera Funds Management added most to Johnson & Johnson in Q1 2022, an estimated $23.8M increase.
  • Sphera Funds Management's biggest Q1 2022 reduction was AbbVie, cutting an estimated $39.7M.
  • Sphera Funds Management fully exited Microsoft in Q1 2022, selling an estimated $17M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $708M portfolio in Q1 2022.
  • Sphera Funds Management opened 17 new positions and closed 41 in Q1 2022.
  • Sphera Funds Management's portfolio value fell 22% quarter-over-quarter to $708M.

Based on Sphera Funds Management's 13F filing for Q1 2022, filed 16 May 2022.